Cell Therapy Collaboration and Licensing Deals 2016-2026

Description

The definitive benchmark for cell therapy dealmaking

Cell therapy partnering is driven by advanced and highly specialised therapeutic approaches, with deal structures reflecting complex development pathways, manufacturing requirements, and high-value innovation.

This report provides a comprehensive and structured analysis of 1080+ cell therapy collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.

Establish a clear view of market standards

The report enables a precise understanding of how cell therapy deals are structured in practice, allowing you to:

Benchmark comparable transactions with confidence
Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
Define realistic market parameters
Clear insight into how deal terms vary by therapy type, development stage, and partner profile
Support valuation and structuring decisions with evidence
Ground internal discussions in real transaction data rather than assumptions
Understand how leading companies approach dealmaking
Visibility into partner behaviour and recurring deal structures across a technically complex and rapidly evolving therapeutic landscape
Full visibility into deal structure and execution
Beyond headline deal data, the report provides access to underlying contract documents, enabling a detailed understanding of how agreements are constructed in practice.

This includes:

Rights granted and retained
Development and commercialization responsibilities
Financial structures and payment triggers
Key contractual provisions and protections
This level of transparency is critical to understanding how value, risk, and control are allocated within cell therapy partnerships, particularly in areas involving manufacturing scale-up, supply chain considerations, and regulatory complexity.
Designed for real-world BD and strategy use

The report is widely used to:

Structure and benchmark advanced therapy transactions
Prepare for negotiations with well-defined market context
Evaluate licensing, co-development, and platform partnerships
Support internal strategy with robust, defensible data
What's included
1080+ cell therapy collaboration and licensing deals
Financial terms, including upfronts, milestones, and royalties where disclosed
Fully searchable deal directory (by company, therapy type, and development stage)
Direct access to SEC-filed agreements and source documents
Analysis of deal trends, key transactions, and active dealmakers
A trusted, evidence-based reference for cell therapy dealmaking
Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how cell therapy partnerships are structured, negotiated, and valued.

Product Code: CP21161

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in cell therapy dealmaking

2.1. Introduction
2.2. Cell therapy deals over the years
2.3. Most active cell therapy dealmakers
2.4. Cell therapy deals by deal type
2.5. Cell therapy deals by therapy area
2.6. Cell therapy deals by industry sector
2.7. Deal terms for cell therapy deals
- 2.7.1 Cell therapy deals headline values
- 2.7.2 Cell therapy deal upfront payments
- 2.7.3 Cell therapy deal milestone payments
- 2.7.4 Cell therapy royalty rates

Chapter 3 - Leading cell therapy deals

3.1. Introduction
3.2. Top cell therapy deals by value

Chapter 4 - Most active cell therapy dealmakers

4.1. Introduction
4.2. Most active cell therapy dealmakers
4.3. Most active cell therapy deals company profiles

Chapter 5 - Cell therapy contracts dealmaking directory

5.1. Introduction
5.2. Cell therapy contracts dealmaking directory

Chapter 6 - Cell therapy dealmaking by technology type

Deal directory
Deal directory - Cell therapy deals by company A-Z
Deal directory - Cell therapy deals by deal type
Deal directory - Cell therapy deals by therapy area
Deal type definitions
About Biopharma Research Ltd
Current Partnering
Current Agreements
Recent report titles from Current Partnering

Table of figures

Figure 1: Cell therapy deals since 2016
Figure 2: Active cell therapy dealmaking activity since 2016
Figure 3: Cell therapy deals by deal type since 2016
Figure 4: Cell therapy deals by therapy area since 2016
Figure 5: Cell therapy deals by industry sector since 2016
Figure 6: Cell therapy deals with a headline value
Figure 7: Cell therapy deals with an upfront value
Figure 8: Cell therapy deals with a milestone value
Figure 9: Cell therapy deals with a royalty rate value
Figure 10: Top cell therapy deals by value since 2016
Figure 11: Most active cell therapy dealmakers since 2016
Figure 12: Cell therapy deals by technology type since 2016